secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-08-29T23:59:59+00:00
Accession:  0001104659-23-096572
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Pharma Board approves retention program with performance-based equity grants to CEO
--------------------------------------------------------------------------------

- CEO Sumit Aggarwal granted 75,000 performance RSUs and 25,000 performance stock options (exercise price $4.63).
- Awards vest upon earliest of: $35M market cap, $25M capital raise, or change in control.
- Future grants of 60,000 RSUs to CEO and 20,000 RSUs to Head of R&D Vijay Modur, subject to share availability.
- Additional 50,000 stock option for CEO under same condition, with exercise price not greater than $4.63.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923096572/0001104659-23-096572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923096572/tm2325066d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-096572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer